Atomwise Inc. Overview
Pro stress-test →Atomwise is an AI-driven biotechnology company that uses deep learning to explore chemical space and discover novel, drug-like molecules using its proprietary AtomNet platform. The company has transitioned into a pharmaceutical company by nominating its first AI-driven development candidate, a TYK2 inhibitor, marking its shift from a pure collaboration model to building an internal drug pipeline.
Strategic Profile
Pro stress-test →Atomwise's AtomNet platform has computationally screened over three trillion synthesizable chemical compounds across more than 600 disease targets to identify therapeutic candidates. In landmark research, AtomNet was applied to 318 targets through collaborations with over 250 academic labs across 30 countries, successfully identifying novel hits for 235 targets and demonstrating superior hit success rates over traditional high-throughput screening. Programs developed from the platform target immune and inflammatory diseases.
Competitive Landscape
Pro stress-test →As of early 2026, industry tracking shows more than 170 AI-discovered drug programs in clinical development, with multiple platforms supplying candidates. Atomwise competes within the growing AI drug discovery sector against platforms and companies leveraging machine learning for small-molecule discovery, including Exscientia, Benchling, and other AI-native biotech firms. The company differentiates through AtomNet's proven ability to identify novel chemical matter and transition toward internal pipeline development.
Industry Context
Atomwise Inc. operates in AI-Driven Drug Discovery and Biotechnology.
Key facts
Founded: 2012 · Headquarters: San Francisco, US · Revenue: N/A · Market cap: N/A